<p>Madrigal Pharmaceuticals（纳斯达克股票代码：MDGL）在过去三个月内被 5 位分析师分析，揭示了从看涨到看跌的多样化观点。</p>
<p>下表提供了分析师最近评级的简明概述，展示了过去 30 天情绪的变化，并与前几个月进行比较，以提供全面的视角。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>分析师的 12 个月价格目标显示，平均目标为 761.6 美元，高估计为 964.00 美元，低估计为 529.00 美元。当前平均目标较之前的 549.25 美元增加了 38.66%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1771617669_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="价格目标图表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1771617669_0.png"/></p>
<h2>理解分析师评级：全面解析</h2>
<p>通过审视最近的分析师行动，我们可以洞察金融专家如何看待 Madrigal Pharmaceuticals。以下总结概述了主要分析师、他们的最新评估以及对评级和价格目标的调整。</p>
<table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexandria Hammond</td>
<td>B of A Securities</td>
<td>下调</td>
<td>中性</td>
<td>$529.00</td>
<td>$570.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>Barclays</td>
<td>宣布</td>
<td>超配</td>
<td>$964.00</td>
<td>-</td>
</tr>
<tr>
<td>Jonathan Wolleben</td>
<td>Citizens</td>
<td>上调</td>
<td>市场跑赢</td>
<td>$745.00</td>
<td>$527.00</td>
</tr>
<tr>
<td>Yasmeen Rahimi</td>
<td>Piper Sandler</td>
<td>上调</td>
<td>超配</td>
<td>$900.00</td>
<td>$540.00</td>
</tr>
<tr>
<td>William Woods</td>
<td>B. Riley Securities</td>
<td>上调</td>
<td>买入</td>
<td>$670.00</td>
<td>$560.00</td>
</tr>
</tbody>
</table>
<h3>关键洞察：</h3>
<ul>
<li><strong>行动：</strong> 分析师根据市场条件和公司表现调整他们的建议。无论是 ‘维持’、‘上调’ 还是 ‘下调’ 他们的立场，反映了他们对 Madrigal Pharmaceuticals 近期发展的反应。这些信息提供了分析师对公司当前状态的快照。</li>
<li><strong>评级：</strong> 分析师从定性角度评估股票，评级范围从 ‘跑赢大盘’ 到 ‘跑输大盘’。这些评级传达了对 Madrigal Pharmaceuticals 相对于更广泛市场的相对表现的预期。</li>
<li><strong>价格目标：</strong> 分析师预测价格目标的变动，提供对 Madrigal Pharmaceuticals 未来价值的估计。审视当前和之前的目标提供了分析师不断变化的预期的洞察。</li>
</ul>
<p>理解这些分析师评估与关键财务指标相结合，可以为 Madrigal Pharmaceuticals 的市场地位提供有价值的洞察。保持信息灵通，做出深思熟虑的决策，参考我们的评级表。</p>
<p>随时了解 Madrigal Pharmaceuticals 的分析师评级。</p>
<h2>揭示 Madrigal Pharmaceuticals 背后的故事</h2>
<p>Madrigal Pharmaceuticals Inc 是一家生物制药公司，专注于提供针对代谢功能障碍相关脂肪肝炎（MASH）的新型治疗方案，这是一种严重的肝脏疾病，具有很高的未满足医疗需求，可能导致肝硬化、肝衰竭和过早死亡。该公司的药物 Rezdiffra（resmetirom）是一种每日一次的口服肝脏靶向甲状腺激素受体激动剂，旨在针对 MASH 的关键潜在原因。</p>
<h3>Madrigal Pharmaceuticals：财务表现解析</h3>
<p><strong>市值视角：</strong> 该公司的市值低于行业平均水平，表明其相对于同行的规模较小。这种定位可能受到感知增长潜力或运营规模等因素的影响。</p>
<p><strong>收入增长：</strong> Madrigal Pharmaceuticals 在过去 3 个月的收入增长显著。截至 2025 年 9 月 30 日，该公司的收入增长率约为 <strong>362.03%</strong>。这表明公司在收入方面有了显著增加。与竞争对手相比，该公司的增长率低于医疗保健行业的平均水平。</p>
<p><strong>净利润率：</strong> Madrigal Pharmaceuticals 的净利润率超过行业标准，突显了公司的卓越财务表现。公司实现了 <strong>-39.75%</strong> 的净利润率，有效管理成本并实现强劲的盈利能力。</p>
<p><strong>股本回报率（ROE）：</strong> Madrigal Pharmaceuticals 的 ROE 低于行业标准，表明在有效利用股本方面存在困难。ROE 为 <strong>-17.28%</strong>，公司可能面临为股东提供满意回报的挑战。</p>
<p><strong>资产回报率（ROA）：</strong> Madrigal Pharmaceuticals 的 ROA 低于行业平均水平，表明在有效利用资产方面可能存在挑战。ROA 为 <strong>-9.6%</strong>，公司可能面临实现最佳财务回报的障碍。</p>
<p><strong>债务管理：</strong> Madrigal Pharmaceuticals 的债务与股本比率显著高于行业平均水平。该比率为 <strong>0.55</strong>，表明公司在借款方面依赖较大，显示出较高的财务风险。</p>
<h2>分析师评级的核心：每位投资者应知晓的事项</h2>
<p>银行和金融系统的专家，分析师专注于特定股票或定义的行业进行报告。他们的全面研究包括参加公司电话会议和会议，分析财务报表，并与内部人士互动，以生成所谓的股票分析师评级。通常，分析师每季度评估和评级每只股票一次。</p>
<p>一些分析师发布他们对增长预期、收益和收入等指标的预测，以便为他们的评级提供额外的指导。在使用分析师评级时，重要的是要记住，股票和行业分析师也是人，他们只是向投资者提供自己的意见。</p>
<p>本文由 Benzinga 的自动内容引擎生成，并经过编辑审核。</p>

基因改革 ETF - ARK

医疗业 ETF - Vanguard

纽交所高增长板生物技术指数 ETF - First Trust

<p>Madrigal Pharmaceuticals（纳斯达克代码：MDGL）在过去三个月内获得了 5 位分析师的混合评级，12 个月的平均目标价为 761.6 美元，比 549.25 美元上涨了 38.66%。最近的行动包括美银证券将其评级下调至中性，以及巴克莱和派珀·桑德勒将其评级上调至增持。该公司专注于代谢功能障碍相关性脂肪肝炎的治疗，显示出 362.03% 的显著收入增长，但面临着股本回报率和资产回报率低的挑战。分析师的评级反映了他们基于市场条件和公司表现不断变化的预期</p>

<p>Madrigal Pharmaceuticals (NASDAQ: MDGL) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<div class="lb-trans"><p>Madrigal Pharmaceuticals（纳斯达克股票代码：MDGL）在过去三个月内被 5 位分析师分析，揭示了从看涨到看跌的多样化观点。</p>
</div><p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<div class="lb-trans"><p>下表提供了分析师最近评级的简明概述，展示了过去 30 天情绪的变化，并与前几个月进行比较，以提供全面的视角。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $761.6, a high estimate of $964.00, and a low estimate of $529.00. This current average has increased by 38.66% from the previous average price target of $549.25.</p>
<div class="lb-trans"><p>分析师的 12 个月价格目标显示，平均目标为 761.6 美元，高估计为 964.00 美元，低估计为 529.00 美元。当前平均目标较之前的 549.25 美元增加了 38.66%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1771617669_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1771617669_0.png"/></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<div class="lb-trans"><h2>理解分析师评级：全面解析</h2>
</div><p>In examining recent analyst actions, we gain insights into how financial experts perceive Madrigal Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>通过审视最近的分析师行动，我们可以洞察金融专家如何看待 Madrigal Pharmaceuticals。以下总结概述了主要分析师、他们的最新评估以及对评级和价格目标的调整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexandria Hammond</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$529.00</td>
<td>$570.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$964.00</td>
<td>-</td>
</tr>
<tr>
<td>Jonathan Wolleben</td>
<td>Citizens</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$745.00</td>
<td>$527.00</td>
</tr>
<tr>
<td>Yasmeen Rahimi</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$900.00</td>
<td>$540.00</td>
</tr>
<tr>
<td>William Woods</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$670.00</td>
<td>$560.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexandria Hammond</td>
<td>B of A Securities</td>
<td>下调</td>
<td>中性</td>
<td>$529.00</td>
<td>$570.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>Barclays</td>
<td>宣布</td>
<td>超配</td>
<td>$964.00</td>
<td>-</td>
</tr>
<tr>
<td>Jonathan Wolleben</td>
<td>Citizens</td>
<td>上调</td>
<td>市场跑赢</td>
<td>$745.00</td>
<td>$527.00</td>
</tr>
<tr>
<td>Yasmeen Rahimi</td>
<td>Piper Sandler</td>
<td>上调</td>
<td>超配</td>
<td>$900.00</td>
<td>$540.00</td>
</tr>
<tr>
<td>William Woods</td>
<td>B. Riley Securities</td>
<td>上调</td>
<td>买入</td>
<td>$670.00</td>
<td>$560.00</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>关键洞察：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Madrigal Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Madrigal Pharmaceuticals compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Madrigal Pharmaceuticals's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>行动：</strong> 分析师根据市场条件和公司表现调整他们的建议。无论是 ‘维持’、‘上调’ 还是 ‘下调’ 他们的立场，反映了他们对 Madrigal Pharmaceuticals 近期发展的反应。这些信息提供了分析师对公司当前状态的快照。</li>
<li><strong>评级：</strong> 分析师从定性角度评估股票，评级范围从 ‘跑赢大盘’ 到 ‘跑输大盘’。这些评级传达了对 Madrigal Pharmaceuticals 相对于更广泛市场的相对表现的预期。</li>
<li><strong>价格目标：</strong> 分析师预测价格目标的变动，提供对 Madrigal Pharmaceuticals 未来价值的估计。审视当前和之前的目标提供了分析师不断变化的预期的洞察。</li>
</ul>
</div><p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Madrigal Pharmaceuticals's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<div class="lb-trans"><p>理解这些分析师评估与关键财务指标相结合，可以为 Madrigal Pharmaceuticals 的市场地位提供有价值的洞察。保持信息灵通，做出深思熟虑的决策，参考我们的评级表。</p>
</div><p>Stay up to date on Madrigal Pharmaceuticals analyst ratings.</p>
<div class="lb-trans"><p>随时了解 Madrigal Pharmaceuticals 的分析师评级。</p>
</div><h2>Unveiling the Story Behind Madrigal Pharmaceuticals</h2>
<div class="lb-trans"><h2>揭示 Madrigal Pharmaceuticals 背后的故事</h2>
</div><p>Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.</p>
<div class="lb-trans"><p>Madrigal Pharmaceuticals Inc 是一家生物制药公司，专注于提供针对代谢功能障碍相关脂肪肝炎（MASH）的新型治疗方案，这是一种严重的肝脏疾病，具有很高的未满足医疗需求，可能导致肝硬化、肝衰竭和过早死亡。该公司的药物 Rezdiffra（resmetirom）是一种每日一次的口服肝脏靶向甲状腺激素受体激动剂，旨在针对 MASH 的关键潜在原因。</p>
</div><h3>Madrigal Pharmaceuticals: Financial Performance Dissected</h3>
<div class="lb-trans"><h3>Madrigal Pharmaceuticals：财务表现解析</h3>
</div><p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<div class="lb-trans"><p><strong>市值视角：</strong> 该公司的市值低于行业平均水平，表明其相对于同行的规模较小。这种定位可能受到感知增长潜力或运营规模等因素的影响。</p>
</div><p><strong>Revenue Growth:</strong> Madrigal Pharmaceuticals's revenue growth over a period of 3M has been noteworthy. As of 30 September, 2025, the company achieved a revenue growth rate of approximately <strong>362.03%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<div class="lb-trans"><p><strong>收入增长：</strong> Madrigal Pharmaceuticals 在过去 3 个月的收入增长显著。截至 2025 年 9 月 30 日，该公司的收入增长率约为 <strong>362.03%</strong>。这表明公司在收入方面有了显著增加。与竞争对手相比，该公司的增长率低于医疗保健行业的平均水平。</p>
</div><p><strong>Net Margin:</strong> Madrigal Pharmaceuticals's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-39.75%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<div class="lb-trans"><p><strong>净利润率：</strong> Madrigal Pharmaceuticals 的净利润率超过行业标准，突显了公司的卓越财务表现。公司实现了 <strong>-39.75%</strong> 的净利润率，有效管理成本并实现强劲的盈利能力。</p>
</div><p><strong>Return on Equity (ROE):</strong> Madrigal Pharmaceuticals's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-17.28%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<div class="lb-trans"><p><strong>股本回报率（ROE）：</strong> Madrigal Pharmaceuticals 的 ROE 低于行业标准，表明在有效利用股本方面存在困难。ROE 为 <strong>-17.28%</strong>，公司可能面临为股东提供满意回报的挑战。</p>
</div><p><strong>Return on Assets (ROA):</strong> Madrigal Pharmaceuticals's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-9.6%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<div class="lb-trans"><p><strong>资产回报率（ROA）：</strong> Madrigal Pharmaceuticals 的 ROA 低于行业平均水平，表明在有效利用资产方面可能存在挑战。ROA 为 <strong>-9.6%</strong>，公司可能面临实现最佳财务回报的障碍。</p>
</div><p><strong>Debt Management:</strong> Madrigal Pharmaceuticals's debt-to-equity ratio is notably higher than the industry average. With a ratio of <strong>0.55</strong>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<div class="lb-trans"><p><strong>债务管理：</strong> Madrigal Pharmaceuticals 的债务与股本比率显著高于行业平均水平。该比率为 <strong>0.55</strong>，表明公司在借款方面依赖较大，显示出较高的财务风险。</p>
</div><h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<div class="lb-trans"><h2>分析师评级的核心：每位投资者应知晓的事项</h2>
</div><p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<div class="lb-trans"><p>银行和金融系统的专家，分析师专注于特定股票或定义的行业进行报告。他们的全面研究包括参加公司电话会议和会议，分析财务报表，并与内部人士互动，以生成所谓的股票分析师评级。通常，分析师每季度评估和评级每只股票一次。</p>
</div><p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<div class="lb-trans"><p>一些分析师发布他们对增长预期、收益和收入等指标的预测，以便为他们的评级提供额外的指导。在使用分析师评级时，重要的是要记住，股票和行业分析师也是人，他们只是向投资者提供自己的意见。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自动内容引擎生成，并经过编辑审核。</p>
</div>

Madrigal 制药股票：深入探讨分析师观点（5 个评级）